Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.DozQrLpG.js ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Pfizer's adjusted EPS of $0.63 surpassed the expected $0.47. Revenue reached $17.8 billion, exceeding the anticipated $17.35 ...

"Our revenue volatility is largely in the past as COVID-related uncertainties have diminished," Pfizer's finance chief David ...

Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment.

Pfizer expects to sufficiently de-lever its balance sheet ... the potential to return capital to shareholders through share repurchases. Fourth-quarter 2024 Comirnaty (1) revenues of $3.4 billion ...

Pfizer reported strong 2024 profits Wednesday on the same day the Connecticut Attorney General’s office released a statement ...

Pfizer (NYSE: PFE) posted adjusted earnings per share of $0.63 for Q4, exceeding the analyst consensus of $0.48. Revenue came ...

Revenue from COVID vaccine Comirnaty brought in sales of $3.38-billion, while antiviral treatment Paxlovid was $727-million for the quarter. Pfizer makes the Comirnaty vaccine with German partner ...

Despite a significant year-over-year decline in Comirnaty revenue, the overall performance was strong, driven by growth in non-COVID-19 products and strategic acquisitions. Source: Pfizer.

but are still a profit driver for Pfizer. Revenue from Covid vaccine Comirnaty brought in sales of $3.38 billion, while antiviral treatment Paxlovid was $727m for the quarter. Pfizer makes the ...